OR WAIT 15 SECS
BioMed X has announced the successful completion of its first joint research project in the fields of COPD and IPF that it had undertaken with Boehringer Ingelheim.
In a Dec. 2, 2019 press release, BioMed X has announced the successful completion of its first joint research project in the fields of chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) that it had undertaken with Boehringer Ingelheim.
The project, which lasted four years, was led by Dr. Renata Jurkowska and involved the systematic exploration of epigenetic regulators in different cell types of the human lung as a potential new target class for the treatment of chronic and disabling lung diseases. Successful identification of a set of new potentially disease-modifying drug targets in lung fibroblasts and alveolar type II (ATII) cells was achieved thanks to the comparison between epigenetic and transcriptomic profiles from patients the project team made.
As a result of the project’s success, BioMed X received a milestone payment. Additionally, Boehringer Ingelheim have been given all the results of the project and will further validate the new target candidates.
“We are very excited about this first joint success with Boehringer Ingelheim,” said Christian Tidona, founder and managing director of BioMed X, in the press release. “This clearly shows how a BioMed X project can be an efficient entry point for big pharma into new areas of research such as epigenetics.”
Source: BioMed X